Nicotine-like behavioral effects of the minor tobacco alkaloids nornicotine, anabasine, and anatabine in male rodents.
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Tobacco use is associated with lethal diseases in an estimated 440,000 persons in the United States each year (Centers for Disease Control and Prevention, 2005). Successful smoking quit-rates are estimated at 5%-8%, even though a quarter of those attempts included use of smoking-cessation aids (Messer et al., 2008; Henningfield et al., 2009). Current projections are that 16% of the U.S. population-35 million people-will still smoke in 2025, thus more effective smoking-cessation aids are urgently needed (Pollock et al., 2009). The minor tobacco alkaloids may be promising candidates, but further research is necessary (Hoffman & Evans, 2013). Accordingly, we systematically evaluated the minor tobacco alkaloids nornicotine, anabasine, and anatabine using assays of behavioral tolerability, nicotine withdrawal, nicotine discrimination, and nicotine self-administration in male rodents. At doses that were well tolerated, all 3 minor alkaloids dose-dependently engendered robust substitution for a nicotine discriminative stimulus in mice (0.32 mg/kg, IP), and anabasine attenuated nicotine withdrawal. When the ED50 dose of each alkaloid was administered in combination with nicotine, the discriminative stimulus effects of nicotine were not enhanced by any of the alkaloids, and anatabine blunted nicotine's effects. In drug self-administration studies, only nornicotine was self-administered by rats that self-administered nicotine intravenously; anabasine and anatabine had no reinforcing effects. Moreover, prior administration of each of the minor tobacco alkaloids dose-dependently decreased nicotine self-administration. Collectively these results suggest that the minor tobacco alkaloids may substitute for the subjective effects of nicotine and attenuate withdrawal and craving without the abuse liability of nicotine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corrigall, W. A., Coen, K. M., & Adamson, K. L. (1994) · Brain Research · doi:10.1016/0006-8993(94)90401-4 · Cited by 740
Dramatic decreases in brain reward function during nicotine withdrawal
Epping-Jordan, M. P., Watkins, S. S., Koob, G. F., & Markou, A. (1998) · Nature · doi:10.1038/30001 · Cited by 674
Pharmacology of Nicotine: Addiction and Therapeutics
Benowitz, N. L. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.003121 · Cited by 589 · cited 1×
“Nicotine is the psychoactive compound presumably responsible for the reinforcing and dependence producing effects of tobacco (Benowitz, 1996; Harvey et al., 2004; Le Foll and Goldberg, 2009; Stolerman & Jarvis, 1995), and accounts for 95% of all alkaloids in tobacco.”
BackgroundLuetje, C., & Patrick, J. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-03-00837.1991 · Cited by 558
Rodent model of nicotine abstinence syndrome
Malin, D. H., Lake, J. R., Newlin-Maultsby, P., Roberts, L. K., Lanier, J. G., Carter, V. A., Cunningham, J. S., & Wilson, O. B. (1992) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(92)90408-8 · Cited by 334 · cited 3×
“Nicotine withdrawal in rodents has been characterized by somatic signs (Kota et al., 2007; Malin et al., 1992; O’Dell et al., 2004), by behavioral disruption as measured by decreased food-reinforced responding (Corrigall et al.”
BackgroundNicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities
HUGHES, J. R., HIGGINS, S. T., & BICKEL, W. K. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03744.x · Cited by 312
Characterization of spontaneous and precipitated nicotine withdrawal in the mouse
Damaj, M. I., Kao, W., & Martin, B. R. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.054908 · Cited by 222 · cited 1×
“Although a variety of neurotransmitter systems have been implicated in the nicotine withdrawal syndrome, a central role for the 4 2 nicotine receptor has been suggested (Damaj et al., 2003; Malin et al., 1998).”
BackgroundNicotine dependence and reward differ between adolescent and adult male mice
Kota, D., Martin, B. R., Robinson, S. E., & Damaj, M. I. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121616 · Cited by 202
Rodent models of nicotine withdrawal syndrome
Malin, D. H., & Goyarzu, P. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_14 · Cited by 89
Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.
Raybuck, J. D., Portugal, G. S., Lerman, C., & Gould, T. J. (2008) · Behavioral Neuroscience · doi:10.1037/a0012601 · Cited by 62
Cited by
Bornebusch, A. B., Fink-Jensen, A., Wörtwein, G., Seeley, R. J., & Thomsen, M. (2019) · eneuro · doi:10.1523/eneuro.0443-18.2019 · Cited by 72
Self-citationAddiction-Related Outcomes of Nicotine and Alcohol Co-use: New Insights Following the Rise in Vaping
Frie, J. A., Nolan, C. J., Murray, J. E., & Khokhar, J. Y. (2022) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntab231 · Cited by 53
Marusich, J. A., Darna, M., Wilson, A. G., Denehy, E. D., Ebben, A., Deaciuc, A. G., Dwoskin, L. P., Bardo, M. T., Lefever, T. W., Wiley, J. L., et al. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.08.029 · Cited by 16
Metadata
- Authors
- Caine, S. B., Collins, G. T., Thomsen, M., Wright, C., Lanier, R. K., & Mello, N. K.
- Venue
- Experimental and Clinical Psychopharmacology
- Published
- 2014
- Volume
- 22
- Issue
- 1
- Pages
- 9-22
- ISSN
- 1064-1297 (ISSN-L)
- 1936-2293
- OpenAlex
- W2329529242
- Cited by
- 66
- References
- 10
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.